vs
Side-by-side financial comparison of Commercial Vehicle Group, Inc. (CVGI) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $154.8M, roughly 1.1× Commercial Vehicle Group, Inc.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -5.2%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -10.8%).
WABCO Holdings, Inc. was a U.S.-based provider of electronic braking, stability, suspension and transmission automation systems for heavy-duty commercial vehicles. In 2007, the Vehicle Control Systems was spun off as WABCO Holdings Inc., an American provider of electronic braking, stability, suspension and transmission automation systems for heavy-duty commercial vehicles. Their products are present in many commercial vehicles such as trucks, buses, trailers and off-highway vehicles but they ...
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
CVGI vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $154.8M | $177.4M |
| Net Profit | — | $2.9M |
| Gross Margin | 9.7% | — |
| Operating Margin | -1.2% | 3.9% |
| Net Margin | — | 1.6% |
| Revenue YoY | -5.2% | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $154.8M | $196.9M | ||
| Q3 25 | $152.5M | $179.5M | ||
| Q2 25 | $172.0M | $181.1M | ||
| Q1 25 | $169.8M | $168.9M | ||
| Q4 24 | $163.3M | $187.3M | ||
| Q3 24 | $171.8M | $168.6M | ||
| Q2 24 | $193.7M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $-7.1M | $5.4M | ||
| Q2 25 | $-4.8M | $-4.8M | ||
| Q1 25 | $-4.3M | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $9.5M | $-143.5M | ||
| Q2 24 | $-1.6M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 9.7% | 79.5% | ||
| Q3 25 | 10.5% | 80.9% | ||
| Q2 25 | 11.4% | 77.4% | ||
| Q1 25 | 10.5% | 79.7% | ||
| Q4 24 | 8.0% | 78.7% | ||
| Q3 24 | 9.6% | 76.9% | ||
| Q2 24 | 10.6% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -1.2% | 1.2% | ||
| Q3 25 | -0.7% | 3.5% | ||
| Q2 25 | 0.5% | 4.7% | ||
| Q1 25 | 0.8% | 1.2% | ||
| Q4 24 | -3.2% | 13.2% | ||
| Q3 24 | -0.6% | -82.8% | ||
| Q2 24 | 0.5% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | -4.6% | 3.0% | ||
| Q2 25 | -2.8% | -2.7% | ||
| Q1 25 | -2.5% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.5% | -85.1% | ||
| Q2 24 | -0.8% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | — | $0.05 | ||
| Q3 25 | — | $0.12 | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | — | $0.38 | ||
| Q3 24 | — | $-3.11 | ||
| Q2 24 | $-0.05 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $144.3M |
| Total DebtLower is stronger | $104.9M | — |
| Stockholders' EquityBook value | $133.4M | $653.9M |
| Total Assets | $391.7M | $1.2B |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $104.9M | $372.2M | ||
| Q3 25 | $108.2M | $376.7M | ||
| Q2 25 | $118.2M | $580.5M | ||
| Q1 25 | $117.4M | $583.4M | ||
| Q4 24 | $135.5M | $585.3M | ||
| Q3 24 | $128.8M | — | ||
| Q2 24 | $142.0M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $133.4M | $693.1M | ||
| Q3 25 | $136.5M | $727.2M | ||
| Q2 25 | $142.6M | $757.8M | ||
| Q1 25 | $136.7M | $798.5M | ||
| Q4 24 | $135.6M | $778.3M | ||
| Q3 24 | $179.3M | $749.6M | ||
| Q2 24 | $169.6M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $391.7M | $1.3B | ||
| Q3 25 | $400.3M | $1.3B | ||
| Q2 25 | $429.8M | $1.5B | ||
| Q1 25 | $419.8M | $1.6B | ||
| Q4 24 | $424.6M | $1.6B | ||
| Q3 24 | $495.3M | $1.5B | ||
| Q2 24 | $503.2M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.79× | 0.54× | ||
| Q3 25 | 0.79× | 0.52× | ||
| Q2 25 | 0.83× | 0.77× | ||
| Q1 25 | 0.86× | 0.73× | ||
| Q4 24 | 1.00× | 0.75× | ||
| Q3 24 | 0.72× | — | ||
| Q2 24 | 0.84× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $12.3M | — |
| Free Cash FlowOCF − Capex | $8.7M | — |
| FCF MarginFCF / Revenue | 5.6% | — |
| Capex IntensityCapex / Revenue | 2.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $34.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $12.3M | $43.7M | ||
| Q3 25 | $-1.7M | $60.8M | ||
| Q2 25 | $18.9M | $12.0M | ||
| Q1 25 | $15.2M | $35.5M | ||
| Q4 24 | $-26.6M | $33.1M | ||
| Q3 24 | $-17.1M | $53.9M | ||
| Q2 24 | $12.6M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $8.7M | $43.5M | ||
| Q3 25 | $-3.5M | $57.0M | ||
| Q2 25 | $17.4M | $9.3M | ||
| Q1 25 | $11.4M | $26.9M | ||
| Q4 24 | $-30.6M | $31.0M | ||
| Q3 24 | $-20.3M | $49.8M | ||
| Q2 24 | $6.4M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 5.6% | 22.1% | ||
| Q3 25 | -2.3% | 31.7% | ||
| Q2 25 | 10.1% | 5.1% | ||
| Q1 25 | 6.7% | 15.9% | ||
| Q4 24 | -18.7% | 16.6% | ||
| Q3 24 | -11.8% | 29.6% | ||
| Q2 24 | 3.3% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.3% | 0.1% | ||
| Q3 25 | 1.2% | 2.2% | ||
| Q2 25 | 0.9% | 1.5% | ||
| Q1 25 | 2.2% | 5.1% | ||
| Q4 24 | 2.4% | 1.1% | ||
| Q3 24 | 1.9% | 2.4% | ||
| Q2 24 | 3.2% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.79× | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CVGI
| Global Seating | $70.7M | 46% |
| Global Electrical Systems | $49.7M | 32% |
| Trim Systems And Components | $34.4M | 22% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
